Randomized phase II study of irinotecan and cisplatin or irinotecan, cisplatin and etoposide in patients with extensive small-cell lung cancer
Phase 2
- Conditions
- Extensive small-cell lung cancer
- Registration Number
- JPRN-C000000120
- Lead Sponsor
- Division of Medical Oncology, National Cancer Center Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 110
Inclusion Criteria
Not provided
Exclusion Criteria
1) uncontrollable pleural, pericardial effusion or ascites; 2) symptomatic brain metastasis; 3) active infection;4) contraindications for the use of irinotecan, including diarrhea, ileus, interstitial pneumonitis and lung fibrosis; 5) synchronous active malignancies; 6) serious concomitant medical illness, including severe heart disease, uncontrollable diabetes mellitus or hypertension; or 7) pregnancy or breast feeding.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method median survival time
- Secondary Outcome Measures
Name Time Method